FDA-Approved Indications for Prozac (Fluoxetine) in Adolescents
Prozac is FDA-approved for two indications in adolescents: Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD). 1
Specific FDA-Approved Indications
1. Major Depressive Disorder (MDD)
- Approved for children and adolescents based on two 8- to 9-week placebo-controlled clinical trials in depressed outpatients whose diagnoses corresponded to DSM-III-R or DSM-IV criteria for major depressive disorder 1
- Fluoxetine is the ONLY antidepressant FDA-approved for use in children and adolescents with depression (escitalopram is approved only for adolescents aged 12 years and older, not younger children) 2
- This represents a critical distinction in clinical practice, as fluoxetine has the broadest pediatric approval for depression 3, 4
2. Obsessive-Compulsive Disorder (OCD)
- Approved for children and adolescents based on a 13-week, dose-titration clinical trial in patients with OCD as defined in DSM-IV 1
- Efficacy demonstrated with doses ranging from 10 to 60 mg/day 1
- Meta-analysis confirms fluoxetine is associated with significantly greater reduction in OCD severity as measured by CY-BOCS, NIMH-OC, and CGI-S scales 5
NOT FDA-Approved in Adolescents
The following indications are NOT FDA-approved for adolescents, despite adult approval:
- Bulimia Nervosa (adult indication only)
- Panic Disorder (adult indication only)
Clinical Context and Dosing
For MDD in adolescents:
- Starting dose: 10 mg/day
- Effective dose: 20 mg/day
- Maximum dose: 60 mg/day 2
For OCD in adolescents:
- Adolescents and higher-weight children: Start 10 mg/day, increase to 20 mg/day after 2 weeks
- Dose range: 20-60 mg/day 1
Important Safety Considerations
All adolescents treated with Prozac require close monitoring for suicidality, clinical worsening, and unusual behavioral changes, particularly during the initial months of treatment or during dose changes, per FDA black-box warning 2. The number needed to harm for suicidality is 112, while the number needed to treat for MDD is 10, yielding a favorable risk-benefit ratio of 1 to 11.2 4.